Cancer & Disease Research
NIH adds long-acting antibody COVID-19 therapy to ACTIV-3 master protocol
The National Institutes of Health (NIH) has begun a new arm of its master protocol, the Accelerating COVID-19 Therapeutic Interventions and Vaccines 3 (ACTIV-3) study, which evaluates the safety and efficacy of an investigational long-acting antibody combination for the treatment of patients hospitalized with COVID-19. Read More
SARS-CoV-2 mutation doesn't affect viral spread, but may limit therapies
As SARS-CoV-2 spreads around the globe, mutations of the virus are inevitable. An international team of researchers sought to define the effects of a specific receptor-binding motif mutation on viral fitness, clinical outcomes, and resistance to therapeutic antibodies. The findings of the study were published on January 28 in Cell. Read More
2003 SARS-CoV antibodies may provide some protection from SARS-CoV-2
A new study shows that antibodies against the original 2003 SARS-CoV also react with the current SARS-CoV-2 strain, but only with limited effectiveness. The findings were published in Cell Reports on January 25. Read More
What makes immuno-oncology therapies attractive investments?
Although immuno-oncology therapies have been around for many years, investors are excited to partner with innovators in the space who can push the boundaries of what these therapies are able to achieve. A panel of investors and business development executives discussed what exactly makes a specific candidate attractive as a business opportunity during a recorded session at the Biotech Showcase virtual event. Read More
Researchers discover important 2nd SARS-CoV-2 receptor
Researchers have identified a second receptor that might be important in SARS-CoV-2 infectivity, according to a new report published in Science on October 20. This cofactor helps facilitate virus-host cell interactions in cells with low levels of angiotensin-converting enzyme 2, the primary receptor on host cells, and might explain the increased pathogenicity of SARS-CoV-2. Read More
Passive vaccines with mAbs may be effective for COVID-19
Monoclonal antibodies (mAbs) isolated from the blood of recovered COVID-19 patients -- known colloquially as "convalescent plasma" -- could be potentially useful as therapeutic and prophylactic agents for passive vaccination, assuming their administration does not trigger unwanted side effects. The findings of the new study were published in Cell on September 26. Read More
Antibody fragments may be exceptionally effective against SARS-CoV-2
An engineered antibody fragment has been developed as a highly potent neutralizer of SARS-CoV-2. For the first time, one of these tiny molecules has been tested for efficacy in in vitro and in vivo infection models. The results of the collaborative study were published in Cell on September 14. Read More
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with its deep cell characterization capabilities. These efforts are highlighted by the rapid impact that Berkeley Lights' Beacon systems had during the early days of the COVID-19 pandemic. Read More
New approach to cancer immunotherapies combines 2 mAb treatments
A new approach to increasing the effectiveness of current cancer immunotherapies combines existing therapies with new monoclonal antibodies (mAb) that block inhibitory cytokines in tumor microenvironments, allowing the body to effectively eliminate tumors. The results of the study were published in Nature Communications on September 11. Read More
Gum disease may affect COVID-19 severity
Patients with inflammation caused by periodontitis may experience more severe COVID-19 complications, according to an article published online July 30 in the Journal of the California Dental Association. Read More
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter